Opinion|Videos|January 31, 2025
Comanaging Cases of RR/MM in Patients Receiving CAR T
Panelists discuss how successful comanagement of CAR T-cell therapy cases requires close coordination between academic centers and community practices, with structured protocols for monitoring, communication, and patient handoffs, while addressing challenges in referral timing, resource allocation, and long-term follow-up care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Describe your institution’s approach to the comanagement and comonitoring of patients receiving CAR T-cell therapy, particularly in the transition back to the community setting.
- Dr Abdallah to ask Dr Kort: Can you share any specific strategies or tools your institution utilizes to facilitate seamless transitions of care between the academic center and community practices for patients receiving CAR T-cell therapy?
- Dr Abdallah to ask Dr Mahmoudjafari: What are the most common challenges you have encountered in the CAR T referral process, and how have you addressed them at your institution?
- Dr Abdallah to ask Dr Mushtaq: What advice would you provide to community physicians regarding the appropriate timing and preparation for referring patients for CAR T therapy?
- Dr Abdallah to ask Dr Kort: Can you share any examples of successful collaborations between your academic center and community practices in the context of CAR T therapy for multiple myeloma?
- Dr Abdallah to ask Dr Mahmoudjafari: What are the most important lessons your institution has learned in the integration of CAR T therapy into the multiple myeloma treatment landscape?
Advertisement
Related to this article
Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.
Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.
Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.
The FDA granted RMAT and fast track designations to prizlon-cel, a CD20/CD19 CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Findings from the phase 3 VOLGA trial support the FDA approval of perioperative durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer.
Adding trotabresib to chemoradiotherapy did not improve progression-free or overall survival and was associated with more dose reductions and interruptions.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5